Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and dissemina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Papp-Wallace, Krisztina M., Bethel, Christopher R., Caillon, Jocelyne, Barnes, Melissa D., Potel, Gilles, Bajaksouzian, Saralee, Rutter, Joseph D., Reghal, Amokrane, Shapiro, Stuart, Taracila, Magdalena A., Jacobs, Michael R., Bonomo, Robert A., Jacqueline, Cédric
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496078/
https://ncbi.nlm.nih.gov/pubmed/30858223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00105-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados